Themed Section: Secretin Family (Class B) G Protein-Coupled Receptors – from Molecular to Clinical Perspectives

REVIEW

The structure and function of the glucagon-like peptide-1 receptor and its ligands

Dan Donnelly

Faculty of Biological Sciences, University of Leeds, Leeds, UK

Glucagon-like peptide-1(7-36)amide (GLP-1) is a 30-residue peptide hormone released from intestinal L cells following nutrient consumption. It potentiates the glucose-induced secretion of insulin from pancreatic beta cells, increases insulin expression, inhibits beta-cell apoptosis, promotes beta-cell neogenesis, reduces glucagon secretion, delays gastric emptying, promotes satiety and increases peripheral glucose disposal. These multiple effects have generated a great deal of interest in the discovery of long-lasting agonists of the GLP-1 receptor (GLP-1R) in order to treat type 2 diabetes. This review article summarizes the literature regarding the discovery of GLP-1 and its physiological functions. The structure, function and sequence–activity relationships of the hormone and its natural analogue exendin-4 (Ex4) are reviewed in detail. The current knowledge of the structure of GLP-1R, a Family B GPCR, is summarized and discussed, before its known interactions with the principle peptide ligands are described and summarized. Finally, progress in discovering non-peptide ligands of GLP-1R is reviewed. GLP-1 is clearly an important hormone linking nutrient consumption with blood sugar control, and therefore knowledge of its structure, function and mechanism of action is of great importance.

LINKED ARTICLES

This article is part of a themed section on Secretin Family (Class B) G Protein-Coupled Receptors. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2012.166.issue-1

Abbreviations

BPh, benzoylphenylalanine; DPPIV, dipeptidyl peptidase IV; DSS, disuccinimidyl suberate; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide-1; GLP-1R, GLP-1 receptor; hGLP-1R, human GLP-1R; NTD, N-terminal domain; rGLP-1R, rat GLP-1R

Introduction

The incretin effect describes the increased secretory response of beta cells, above that of glycaemia itself, which results from the actions of gut-derived factors (McIntyre *et al.*, 1964). Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are the hormones responsible for the incretin effect, and together they account for up to 60% of postprandial insulin release (Nauck *et al.*, 1986). However, despite their equivalent roles in potentiating glucose-induced insulin release, therapeutic strategies for the treatment of type 2 diabetes have focused primarily on GLP-1 since, unlike GIP, it continues to elicit a response in type 2 diabetic patients (Nauck *et al.*, 1993).

GLP-1 is expressed in intestinal L cells and is derived from the cell-specific post-translational processing of the prepro-

glucagon gene (Mojsov *et al.*, 1986). Initially, the peptide GLP-1(1-37) was identified from this processing, but it was the two N-terminally truncated products, GLP-1(7-37) and GLP-1(7-36)amide, that were found to recognize the pancreatic receptor and which were determined to be the active species *in vivo* (Drucker *et al.*, 1987; Holst *et al.*, 1987; Mojsov *et al.*, 1987; Ørskov and Nielsen, 1988; Weir *et al.*, 1989). These two shorter peptides are equipotent (Ørskov *et al.*, 1993) and are the major physiological incretin in humans (Edwards *et al.*, 1999); hence, these N-terminally truncated peptides are the forms implied by the generic term 'GLP-1' throughout this review.

The mechanisms of action of GLP-1 (reviewed extensively by Doyle and Egan, 2007) go beyond just the augmentation of glucose-induced insulin secretion and include increasing insulin expression (Drucker *et al.*, 1987), inhibiting beta-cell

```
                          7       15      22              36
                          |       |       |               |
      GLP-1               HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR
      A7-GLP-1            AAEGTFTSDVSSYLEGQAAKEFIAWLVKGR
      A10-GLP-1           HAEATFTSDVSSYLEGQAAKEFIAWLVKGR
      GLP-1(9-36)           EGTFTSDVSSYLEGQAAKEFIAWLVKGR
      GLP-1(15-36)               DVSSYLEGQAAKEFIAWLVKGR


                          1       9       16              30       39
                          |       |       |               |        |
      Ex4                 HGEGTFTSDLSKQMEEEVARLFIEWLKNGGPSSGAPPPS
      Ex4(1-30)           HGEGTFTSDLSKQMEEEVARLFIEWLKNGG
      Ex4(9-39)                   DLSKQMEEEVARLFIEWLKNGGPSSGAPPPS
      Ex4(9-30)                   DLSKQMEEEVARLFIEWLKNGG
```

Figure 1

A sequence alignment of GLP-1, Ex4 and several analogues mentioned at various stages in the text. All peptides are C-terminally amidated. Note that the first residue of GLP-1 is His[7], while that of Ex4 is His[1]. Residues changed from the original sequence are underlined.

apoptosis and promoting beta-cell neogenesis (Perfetti and Hui, 2004; Cornu and Thorens, 2009); reducing glucagon secretion (Kreymann et al., 1987), delaying gastric emptying (Wettergren et al., 1993; Nauck et al., 1997), promoting satiety (Turton et al., 1996; Flint et al., 1998) and increasing peripheral glucose disposal (D'Alessio et al., 1994; 1995; Egan et al., 2002). It is clear from these varied actions that GLP-1 plays a central role in controlling postprandial blood sugar levels, and hence, the enhancement of GLP-1 action has become an important area for the development of new therapies to treat type 2 diabetes (e.g. Ahrén, 2011). GLP-1 raises insulin and lowers glucagon in type 2 diabetic patients (Nathan et al., 1992; Nauck et al., 1993), and repeated s.c. injections were found to normalize plasma glucose levels (Nauck et al., 1996). However, the half-life of GLP-1 in vivo is short, and it is rapidly degraded to GLP-1(9-36)amide by DPPIV (Deacon et al., 1995; Knudsen and Pridal, 1996; Hansen et al., 1999), and hence, there are continuing attempts to find long-lasting peptide agonists with glucoregulatory properties (e.g. Gong et al., 2011). Indeed, current therapeutic approaches have utilized DPPIV-resistant mimetics of GLP-1, most notably exenatide (Iltz et al., 2006) and liraglutide (Neumiller and Campbell, 2009), both of which are in current therapeutic use. Exenatide is the synthetic form of the naturally occurring peptide exendin-4 (Ex4), originally isolated from the saliva of the Gila monster Heloderma suspectum (Eng et al., 1992). It is 53% identical to GLP-1 but is resistant to DPPIV cleavage, largely due to the substitution of Ala[2] by Gly (Figure 1). Liraglutide, on the other hand, is a synthetic analogue of GLP-1 itself, with minor sequence alterations and a covalently linked C-16 acyl chain.

The receptor for GLP-1 (GLP-1R) was first cloned from a cDNA library derived from rat pancreatic islets (Thorens, 1992), and the following year, the human receptor was cloned (Dillon et al., 1993; Graziano et al., 1993; Thorens et al., 1993). The cloning revealed a receptor sequence of 463 residues that resembled the receptors for secretin, parathyroid hormone and calcitonin. These receptors formed a new branch of the GPCR superfamily, named 'Family B' (or 'Class B', or 'secretin receptor-like'), which to date includes 15 members (Hoare, 2005). These receptors possess a unique extracellular N-terminal domain (NTD) of 100–150 residues, which is connected to the integral membrane core domain (or J domain) that is typical of all GPCRs.

Family B GPCRs bind their peptide ligands via a common mechanism known as the 'two-domain model' (Bergwitz et al., 1996; Hoare, 2005) in which the NTD first binds to the C-terminal helical region of the ligand, thereby enabling a second interaction between the N-terminal region of the ligand and the core domain of the receptor. The latter interaction is essential for enabling agonist-induced receptor activation. An alternative model to explain Family B GPCR activation has been proposed, in which the ligand-binding event induces a conformational change that exposes an 'endogenous agonist', which then interacts with the receptor core domain to initiate activity (Dong et al., 2006; Dong et al., 2008).

The importance of the ligand's α-helical secondary structure in the two-domain model for mediating the initial interaction with the NTD has been reviewed (Parthier et al., 2009), while a common helix-capping model to explain how the various ligands of Family B GPCRs might activate their receptors has been proposed (Neumann et al., 2008). An example of how knowledge of the two-domain model can be used to design and synthesize novel ligands has recently been described in an elegant study by Devigny et al. (2011), who produced high potency probes with in vivo activity. An azide-modified peptide based upon the C-terminus of the ligand, corticotropin releasing factor, was used as a carrier protein and fused to an acetylene-tagged peptide library from which the activating mimetic of the ligand's N-terminus was derived.

This article will review the structure and function of GLP-1R with particular emphasis upon how it interacts with its peptide ligands. In addition, the sequence– and structure–activity properties of the peptide ligands will be considered, as will the few non-peptide ligands that have been discovered to date.

Peptide ligands

GLP-1

Using perfused rat pancreas, Suzuki *et al.* (1989) demonstrated that the free N-terminal His[7] was important for GLP-1's insulinotropic activity. While GLP-1(7-37) elicited a clear response at 0.1–1 nM, its N-terminally truncated analogue GLP-1(8-37) did not. Moreover, since GLP-1(1-37) and GLP-1(6-37) also failed to initiate activity, it suggested that His[7] was required as the N-terminal residue of the agonist peptide. In contrast, truncation of the two extreme C-terminal residues (Arg[36] and Gly[37]) resulted in a less dramatic effect, although potency was nevertheless reduced. These sequence–activity data were in agreement with the findings of Mojsov (1992), using insulin-secreting RIN1046-38 cells. Radioligand binding demonstrated that the removal of C-terminal residues resulted in a 5- to 10-fold reduction in affinity, whereas removal of the N-terminal His[7] [GLP-1(8-37)], or inclusion of the full N-terminal sequence [GLP-1(1-37)], resulted in greater than 300-fold reduced affinity. Removal of the first 14 residues of GLP-1 yielded a peptide with 1500-fold lower affinity than GLP-1 and with antagonist properties, while removal of the C-terminal 11 residues resulted in undetectable binding and activity (Gallwitz *et al.*, 1990).

A residue-by-residue substitution of the GLP-1 sequence was carried out by Novo Nordisk in 1994 (Adelhorst *et al.*, 1994). Each residue was individually substituted by Ala, unless it was already Ala in which case it was substituted by its equivalent in glucagon (Ala[25] was not studied in this series, presumably because it is also Ala in glucagon). Adenylyl cyclase activity was used to assess agonist potency and intrinsic activity using membranes from RIN-2A18 cells, while competition binding assays were used to assess ligand affinity using membranes derived from Chinese hamster lung cells expressing recombinant rat GLP-1R (rGLP-1R). The binding assays suggested that the N-terminal positions 7, 10, 12, 13 and 15 were important for GLP-1 affinity at rGLP-1R since the substitutions resulted in a 41- to 219-fold increase in IC_{50}. A similar Ala-scan study in the same year, using RINm5F cells, identified the same five residues in the N-terminal region as being important for affinity (132- to 425-fold reduced affinity; Gallwitz *et al.*, 1994). The His[7] substitution by Ala resulted in a 111- to 374-fold reduction in affinity in these two studies, in contrast with only a 10-fold reduction at recombinant human GLP-1R (hGLP-1R) caused by replacing His[7] by Tyr (Xiao *et al.*, 2001). In another study using rGLP-1R expressed in Chinese hamster lymphoblast cells, His[7] to Ala resulted in a 397-fold reduction in affinity, compared with 174-fold reduction by the Tyr substitution (Hareter *et al.*, 1997). Furthermore, the His[7] to Ala substitution resulted in a peptide that displayed no detectable adenylyl cyclase activity using 10 µM peptide, whereas the Tyr substituted peptide had a potency of 34 nM (GLP-1 control EC_{50} was 2.6 nM; Adelhorst *et al.*, 1994; Xiao *et al.*, 2001).

The substitution of Ala[8] with D-Ala resulted in less than a twofold effect on affinity and less than a 10-fold reduction in potency at hGLP1-R (Xiao *et al.*, 2001), while substitution by Ser resulted in a ninefold reduction in affinity at rGLP-1R, with no effect upon potency (Adelhorst *et al.*, 1994). Therefore, Ala[8] appears to be less important to the peptide's func-

tion compared with His[7]. Truncation of both these residues to give GLP-1(9-36)amide (the natural DPPIV cleavage product) yielded a peptide with partial agonist activities. A study using transfected CHO cells expressing recombinant rGLP-1R demonstrated that GLP-1(9-36)amide displayed a 94-fold reduced affinity compared with GLP-1 and produced approximately 50% of the cAMP levels at 1 µM compared with that produced by 10 nM GLP-1 (Montrose-Rafizadeh *et al.*, 1997). This partial agonist is present in the circulation at four to five times the level of GLP-1 (Egan *et al.*, 2002), but initial studies did not demonstrate that it produced any biological activity (Vahl *et al.*, 2003). However, it has since been suggested that GLP-1(9-36)amide is indeed insulinotropic, but that its actions are masked by the more potent effects of GLP-1 itself (Elahi *et al.*, 2008).

The N-terminal region also contains other important residues and, indeed, the further truncation of GLP-1, to form GLP-1(15-36)amide, resulted in a 367-fold reduction in affinity (rGLP-1R in CHO cells) and no detectable activity at 1 µM peptide (Montrose-Rafizadeh *et al.*, 1997). Although Glu-9 was not identified as being of particular importance by Adelhorst *et al.* (1994), Xiao *et al.* (2001) demonstrated that its substitution resulted in an 81-fold reduction in affinity and a 30-fold reduction in potency. Adelhorst *et al.* (1994) detected no adenylyl cyclase activity for GLP-1 peptides with either Gly[10] or Asp[15] substituted by Ala, while the Gly[10] to Ala substitution by Xiao *et al.* (2001) resulted in more than 100-fold reduced affinity and greatly reduced potency. Watanabe *et al.* (1994) also studied position 10 and found that substitution by Ala resulted in a 221-fold reduction in affinity, while the D-Ala and β-Ala substitutions had less effect. Siegel *et al.* (1999) demonstrated that substitution of Ser[14] and Asp[15] resulted in significant decrease in affinity and activity at RINm5f cells.

An N-terminal fragment of GLP-1, corresponding to GLP-1(7-17) but with Val[16] and Ser[17] substituted with biphenylalanine derivatives, displayed potency that was only 206-fold lower than GLP-1 itself (Mapelli *et al.*, 2009). Further modification by replacing Ala[2] (by aminoisobutyric acid) and Phe[6] (by α-methyl-phenylalanine derivative) led to the discovery of an 11-mer with potency that was only two to threefold lower than GLP-1. Hence the region of GLP-1 that is essential for activity must be located within positions 7–17. Therefore, although the two domain model suggests that the activating N-terminal region of the peptide agonists must be 'delivered' to the core domain via binding of the C-terminus to the NTD, this 11-mer agonist suggests that it is nevertheless possible to obtain high potency from the secondary interaction.

Adelhorst *et al.* (1994) and Gallwitz *et al.* (1994) also identified both Phe[28] and Ile[29] as being important for GLP-1's activity, probably due to their role in maintaining the helical structure of the peptide as assayed by far-UV CD spectroscopy (Adelhorst *et al.*, 1994). However, many residues in GLP-1 appear not to be critical for affinity or activity, and indeed the discovery and analysis of a GLP-1-like peptide from *Xenopus* reveals that, despite 9 residue substitutions (Phe[12]–Tyr, Ser[14]–Asn, Ser[17]–Thr, Ser[18]–Glu, Gly[22]–Glu, Gln[23]–Lys, Ala[30]–Glu, Val[33]–Ile, Arg[36]–Lys), its affinity and potency at hGLP-1R were nevertheless slightly better than GLP-1 itself (Irwin *et al.*, 1997). The non-involvement of these residues in receptor affinity and efficacy is reflected in the results of the Ala scan

of Adelhorst *et al.* (1994) and Gallwitz *et al.* (1994) with the possible exception of Phe-12 (substitution to Ala resulted in 133-fold reduced affinity and 13-fold reduced potency), although the larger Tyr side chain in the *Xenopus* sequence is likely to be a more acceptable substitution compared with Ala.

Valuable insights into GLP-1 structure and function, as well as potential anti-obesity compounds, have come from studying the features that govern the selectivity between GLP-1 and glucagon at their related receptors. For example, the replacement of the C-terminal sequence 'VKGR' of GLP-1 with the corresponding 'MNT' of glucagon resulted in a 475-fold decrease in affinity. However, the substitution of residues in the N-terminal half of GLP-1 for those of glucagon had much smaller effects (Hjorth *et al.*, 1994; Hjorth and Schwartz, 1996). Runge *et al.* (2003a,b) demonstrated, using chimaeric receptors, that the selectivity of GLP-1R for GLP-1 over glucagon is due to the NTD recognising the C-terminus of the peptide, while the toleration of GLP-1R for the glucagon N-terminal sequence results from the core domain. Understanding the specificity requirements for GLP-1 and glucagon at GLP-1R and the glucagon receptor has enabled the design of a co-agonist peptide that eliminates obesity in a rodent model (Day *et al.*, 2009; Day *et al.*, 2010). Full potency was obtained at GLP-1R using a peptide corresponding to glucagon but with changes at just three side chains (Ser16-Glu, Arg18-Ala, Gln20-Lys) and amidation of the C-terminus.

Exendin-4

The study of GLP-1R has been greatly enhanced by the discovery of the peptide agonist exendin-4 (Ex4) from the saliva of the Gila monster *H suspectum* (Eng *et al.*, 1992). Although useful for elucidating aspects of GLP-1R's structure-function, Ex4 is not simply a research tool since, in its synthetic form, it constitutes the drug exenatide (Byetta; Iltz *et al.*, 2006). It was actually the related peptide exendin-3, discovered in *H horridum*, which was discovered first and found to have efficacy in dispersed pancreatic acini (Eng *et al.*, 1990). However, despite only differing by 2 of the 39 residues (Gly2, Glu3 in Ex4, compared with Ser2, Asp3 in exendin-3), Ex4 was found to have distinct pharmacological properties and does not act at VIP or secretin receptors. The N-terminal truncation of the first eight residues of exendin-3 yielded an antagonist that was initially used as a tool to elucidate the pharmacology of exendin-3 (Raufman *et al.*, 1991). However, since exendin-3 and Ex4 are identical from residues 4–39, this antagonist, Ex4(9-39), has become a valuable tool for studying GLP-1R. Ex4 was found to share a similar pharmacological profile to GLP-1 (Raufman *et al.*, 1992) being a potent GLP-1R agonist, while Ex4(9-39) is an antagonist (Göke *et al.*, 1993; Thorens *et al.*, 1993; Schepp *et al.*, 1994; Kolligs *et al.*, 1995). However, while usually described as an antagonist, Ex4(9-39) has also been described as an inverse agonist at the murine GLP-1R (Serre *et al.*, 1998).

Despite their related sequences and similar pharmacological profile, sequence–activity studies using Ex4 have highlighted some clear differences with GLP-1. While the removal of the first two N-terminal residues of GLP-1 yielded a partial agonist with a 100-fold reduction in affinity, Ex4(3-39) has been reported to be a high-affinity antagonist (Montrose-Rafizadeh *et al.*, 1997). Furthermore, while the further trun-

cation of GLP-1 to remove the first eight residues resulted in a peptide with 370-fold reduced affinity [GLP-1(15-36)amide], Ex4(9-39) retains high affinity for GLP-1R. Hence, it is clear that, despite sharing eight of the nine residues at the N-terminus, these regions of the two peptides play a subtly different role in receptor interactions. For example, while the Gly2-Ala substitution in Ex4 is tolerated (Al-Sabah and Donnelly, 2003a; 2004; Patterson *et al.*, 2011a), the converse Ala2-Gly change in GLP-1 reduces affinity by three- to fivefold (Deacon *et al.*, 1998; Burcelin *et al.*, 1999; Patterson *et al.*, 2011a). Therefore, the interaction between the NTD and the C-terminal helix of the ligand can result in a different interaction between the N-terminus and the core domain (Al-Sabah and Donnelly, 2004). Indeed, substitution of Glu22, Glu27 and Ala30 in GLP-1, with Gly, Leu and Glu from Ex4, enabled Gly2 tolerance (Patterson *et al.*, 2011a).

Interestingly, while Ex4(2-39) retains high affinity and full activity at 10 nM, the replacement of Asp9 with Glu resulted in the complete loss of efficacy, despite no effect upon affinity (Montrose-Rafizadeh *et al.*, 1997), suggesting that Asp9 plays an important role in activity.

A large number of GLP-1/Ex4 chimaeric peptides have been utilized in order to understand the determinants that enable Ex4(9-39) to retain potent antagonist activity, while GLP-1(15-36) remains an agonist (Patterson *et al.*, 2011b). Glu16, Val19 and Arg20 were determined to be the essential determinants of Ex4(9-39)'s antagonism, in agreement with earlier chimaeric studies that demonstrated that the 'E16EAVRL' sequence within the N-terminally truncated Ex4 was the determinant of its greater affinity over that of GLP-1(15-36)amide.

Updated data – a new view!

Recent data from the author's laboratory and in Patterson *et al.* (2011b) challenge some of the commonly held views about GLP-1 and Ex4 efficacy. The data reviewed in the sections above clearly point to the N-terminal region of GLP-1 as being essential for activity. However, using recombinant HEK-293 cell lines, it is possible to obtain robust activity for a number of peptide ligands previously believed to be devoid of efficacy (e.g. [His7-Ala]GLP-1; [Gly10-Ala]GLP-1; GLP-1(15-36)amide; Ex4(3-39); Figure 2; Patterson *et al.*, 2011b). It is likely that the receptor reserve in the HEK-293 expression system enables the detection of agonists with low efficacy and therefore provides a useful environment in which to distinguish affinity-generating determinants from those responsible for creating efficacy.

Peptide structures

NMR analysis of GLP-1 in dodecylphosphocholine micelles revealed that, while the N-terminal residues 7–13 are unstructured, the rest of the peptide forms two helices from positions 13–20 and 24–35, separated by a linker region formed around Gly22 (Thornton and Gorenstein, 1994). Parker *et al.* (1998) utilized a number of cross-linked analogues of GLP-1 in order to trap an active conformation. The structures were largely compatible with the two-helix description of Thornton and Gorenstein. In contrast, Ex4 (which has Glu-16 in the equivalent position to Gly22 in GLP-1) forms a single helix spanning residues 11–27 (Neidigh *et al.*, 2001). A recent NMR analysis

A

B

Figure 2

Concentration–response curves (LANCE cAMP assay) for various peptides at hGLP-1R, expressed in HEK-293 cells, using the same cell line as described previously by Mann *et al.* (2010a,b). pEC_{50} values, averaged over three independent experiments, were (A) GLP-1, 11.17 ± 0.12; A7-GLP-1, 9.64 ± 0.09; A10-GLP-1, 9.45 ± 0.08; GLP-1(9-36), 6.97 ± 0.09; GLP-1(15-36), 6.72 ± 0.13. (B) Ex4, 12.14 ± 0.06; Ex4(1-30), 11.42 ± 0.03; Ex4(3-39), 8.87 ± 0.06; Ex(9-39) and Ex4(9-30) gave no response (Nasr, Wishart and Donnelly, unpubl.). Note that several peptides [A7-GLP-1, A10-GLP-1, GLP-1(15-36), Ex4(3-39)], believed to be inactive in other expression systems, display robust activity in HEK-293 cells.

of an analogue of Ex4 with enhanced activity (β-Ala replaces Glu-3, while Tyr replaces Gln-3) has shown a longer helical region that extends towards the N-terminus and that may be responsible for its apparent increase in activity (Wang *et al.*, 2010). The NMR structures of GLP-1 and Ex4 are dependent upon the medium in which they reside (Andersen *et al.*, 2002; Neidigh and Andersen, 2002). In the micelle-bound state, the C-terminal extension of Ex4 (residues 31–39) is disordered. However, in aqueous TFE, this region forms a distinct fold called a Tryptophan-cage (Trp-cage), which has been the seed-corn for parallel studies in the field of protein design and folding (e.g. Neidigh *et al.*, 2002). The literature regarding the role of the putative Trp-cage and/or the C-terminal extension of Ex4 has appeared to be contradictory (Doyle *et al.*, 2003; Al-Sabah and Donnelly, 2003a; Runge *et al.*, 2007). However, this has recently been clarified (Mann *et al.*, 2010b) and will be discussed in more detail later in this review.

GLP-1 receptor

The cloning of GLP-1R (Thorens, 1992; Dillon *et al.*, 1993; Graziano *et al.*, 1993; Thorens *et al.*, 1993) identified it as part of the Family B GPCR family (Segre and Goldring, 1993) and hence intimated that its structure would resemble the two-domain fold common to the sub-group. As with many integral membrane proteins, the experimentally determined structure of a representative Family B GPCR has yet to be achieved, although some progress has been made in expressing, purifying and characterizing the full-length hGLP-1R in an *Escherichia coli* expression system (Schröder-Tittmann *et al.*, 2010). Based upon its amino acid sequence, GLP-1R is

expected to have the seven transmembrane (7TM) bundle typical of all GPCRs (e.g. Palczewski *et al.*, 2000), with the seven α-helices (TM1-TM7) separated by three intracellular loops (ICL1–ICL3) and three extracellular loops (ECL1–ECL3). However, the sequence of Family B GPCRs is devoid of the consensus sequences and motifs that define Family A receptors, with the possible exception of the disulphide bond between ECL1 and ECL2 (Mann *et al.*, 2010a). However, using approaches that were shown to be reasonably successful at predicting the helical arrangements in Family A GPCRs (Donnelly *et al.*, 1989; 1994; Baldwin, 1993), some studies have attempted to predict the features of the core domain of family B GPCRs (Donnelly, 1997; Tams *et al.*, 1998; Frimurer and Bywater, 1999).

A complicating factor in understanding and determining the structure of family B GPCRs may be their tendency to form oligomers. For example, a predicted lipid-exposed face (Donnelly, 1997) of TM4 of the secretin receptor has been implicated in functionally relevant oligomerization (Harikumar *et al.*, 2007). Disruption of this interface using either peptides derived from the sequence of TM4, or site-directed mutagenesis of Gly[243] and Ile[244], demonstrated that the oligomerization mediated by the lipid-exposed face of TM4 was important for the full potency of secretin. Disruption of the interface resulted in an 18- to 28-fold reduction in potency, despite no effect upon ligand affinity. A similar interface has been identified for the calcitonin receptor (Harikumar *et al.*, 2010).

The cloning of GLP-1R suggested the presence of a signal peptide at the extreme N-terminus, and this was shown to be required for the receptor's synthesis in HEK-293 cells (Huang *et al.*, 2010). Cleavage of the signal peptide was essential for

correct processing and trafficking, such that only the mature and fully glycosylated receptor reached the plasma membrane (Huang *et al*., 2010). The N-glycosylation of GLP-1R had previously been demonstrated in RINm5F cells (Göke *et al*., 1994), with glycopeptidase F reducing the apparent molecular weight from 63 to 51 kDa and tunicamycin reducing detectable receptor expression but not ligand affinity. In recombinant CHO cells, mutation of any two of the three N-glycosylation sites resulted in disruption of receptor trafficking to the plasma membrane (Chen *et al*., 2010a). Therefore, it appears that GLP-1R is a glycoprotein, and that the glycosylation, together with the cleavage of the signal peptide, is an essential process in the correct trafficking and processing of the receptor.

GLP-1R signalling

As with family B GPCRs in general, GLP-1R predominantly signals through the Gs G-protein to raise intracellular cAMP levels (Nauck *et al*., 1993; Coopman *et al*., 2010), although coupling to other G-proteins has been observed (Bahekar *et al*., 2007; Doyle and Egan, 2007). The receptor couples to G-proteins via its intracellular loops, and there is some evidence that demonstrates that different regions and residues couple the receptor to different G-proteins. For example, using synthetic peptides to directly activate G-proteins, Hällbrink *et al*. (2001) have shown that the N-terminal half of ICL3 is responsible for Gs coupling, while the C-terminal half mediates signalling via Gi/o.

Nevertheless, it is the cAMP production mediated by GLP-1R activation that constitutes the principle driver of insulin secretion. Transfection of HIT-T15 cells with GLP-1R enabled GLP-1-mediated insulin secretion in contrast to the transfection of two deletion mutants that were known to be uncoupled from Gs (Salapatek *et al*., 1999). Wheeler's group have scanned the intracellular loops using deletion- and site-directed mutagenesis (Takhar *et al*., 1995; Mathi *et al*., 1997) and have shown that Lys[334], along with the two following residues (Leu and Lys), is required for full receptor activity. In addition, Val[327], Ile[328] and Val[331], at the TM5/ICL3 junction, play an important part in coupling the receptor and may contact Gs. ECL2 does not play a significant part in G-protein coupling, but mutation of Arg[176] on ECL1 to Ala reduced receptor activity to about 25% of normal. Heller *et al*. (1996) also identified His[180] as being important for agonist-induced coupling since its mutation to Arg resulted in a 20-fold decrease in affinity and a 50% decrease in cAMP production. In contrast to Takhar *et al*. (1995), Heller *et al*. (1996) also suggest that Arg[348] (ECL3) is critical for receptor activity.

Following agonist-induced receptor activation, GLP-1R is internalized. This may be via a coated pit mechanism following phosphorylation by both homologous and heterologous mechanisms (Widmann *et al*., 1995; 1996a). Further investigation located the phosphorylation sites to Ser[431]/Ser[432], Ser[441]/Ser[442], Ser[444]/Ser[445] and Ser[451]/Ser[452] (Widmann *et al*., 1996b). Alternatively, GLP-1R internalization has been found to be arrestin-independent and associated with caveolin-1 (Syme *et al*., 2006).

N-terminal domain

The two-domain structure of Family B GPCRs lends itself to structural and functional analysis through the isolation of the NTD, an approach that has been extremely useful for studying GLP-1R (Wilmen *et al*., 1996; Xiao *et al*., 2000; Bazarsuren *et al*., 2002; López de Maturana *et al*., 2003; Al-Sabah and Donnelly, 2003a; Mann *et al*., 2007; 2010b; Runge *et al*., 2007; 2008; Underwood *et al*., 2010).

The isolated NTD was expressed and purified from mammalian COS-7 cells and was shown to cross-link to ^{125}I-GLP-1. Using a 6xHis tag, the affinity of the NTD for GLP-1 was estimated to be 450 nM (Xiao *et al*., 2000). Prior to this, Wilmen *et al*. (1996) expressed the isolated NTD of rGLP-1R (residues 20–144) in *E coli* and purified the soluble fraction via a 6xHis tag. The purified protein was expressed at low levels but was shown to be functionally active since it competed with ^{125}I-GLP-1 binding to cells expressing the full-length receptor and could also be cross-linked to ^{125}I-GLP-1 with disuccinimidyl suberate (DSS). Disruption of the disulphide bonds within the NTD using β-mercaptoethanol resulted in its complete loss of ability to compete with ^{125}I-GLP-1 binding to GLP-1R. Bazarsuren *et al*. (2002) also expressed the NTD of hGLP-1R in *E coli*, but, unlike Wilmen *et al*., they isolated the receptor domain from inclusion bodies from which the NTD was denatured, refolded and purified in quantities suitable for biophysical and structural analysis. Interaction with GLP-1 was demonstrated via cross-linking, surface plasmon resonance (SPR) and isothermal titration calorimetry, giving affinity constants for GLP-1 of 46–144 nM. Further analysis demonstrated the presence of three disulphide bonds linking residues 46–71, 62–104 and 85–126. Using this expression/refolding approach, López de Maturana *et al*. (2003) expressed and purified the NTD from rGLP-1R and demonstrated that, while GLP-1 binds with 400 nM affinity, the ligands Ex4, Ex4(3-39) and Ex4(9-39) bind with 1–3 nM affinity. The differential affinity of GLP-1 and Ex4 will be discussed in more detail in the next section.

The isolated NTD of hGLP-1R from the *E coli* inclusion body preparation was biophysically characterized by Runge *et al*. (2007), and the same protocol was used to produce a protein preparation which was incubated with Ex4(9-39), before being further purified, crystallized and analysed using X-ray diffraction (Runge *et al*., 2008). The resultant 2.2Å crystal structure resembled that of other Family B GPCR NTDs, displaying two regions of anti-parallel β-sheet, three disulphide bonds and an N-terminal α-helix (Parthier *et al*., 2009; Figure 3A). The core of the structure contains six conserved residues (Asp[67], Trp[72], Pro[86], Arg[102], Gly[108] and Trp[110]), which are critical for the fold's stability and structure. A ligand-binding groove is present, which is lined by residues on the α-helix, turn 1, loop 2 and the C-terminal region of the NTD.

This inclusion body/refolding approach has been extended to include the full-length receptor that has been obtained in an active form with distinct binding kinetics from those of the autonomously folded NTD (Schröder-Tittmann *et al*., 2010). However, to date, the structure of the full-length receptor remains unknown. An attempt was made to model GLP-1R and its ligand-binding sites using homology modelling with the templates being the crystal structures of the GIP receptor NTD and rhodopsin (Lin and Wang, 2009). More recent modelling (Miller *et al*., 2011) has utilized the X-ray structure of the GLP-1R NTD (Underwood *et al*., 2010) fused to 250 diverse helical bundle domain models from 25

Figure 3

(A) A schematic representation of the structure of the NTD of hGLP-1R based upon the crystal structure of Runge *et al.* (2008). The residue numbers at the boundaries of the various secondary structural elements are shown. Disulphide bonds are depicted with dashed lines. On the right is the α-helical region of Ex4(9-39) with lines connecting to contacting residues on the NTD. (B) *Left*: Ideal helical wheel containing the residues in the helical region of Ex4(9-39). Residues conserved with GLP-1 are filled grey. Interactions with residues in the NTD are shown with solid arrows. Intra-helical interactions, which stabilize the helix, are shown with dotted arrows. The hydrophilic and hydrophobic faces are labelled. *Right*: The helical region of GLP-1 on the C-terminal side of the Gly-22 kink. Note that the helix-stabilizing interactions found in Ex4(9-39) are not formed in GLP-1 since the residues are not conserved.

transmembrane bundles, alongside experimentally derived photo-affinity contacts, in order to further understand the ligand–receptor interactions. Nevertheless, while it appears reasonable to assume that the core domain will interface with the NTD in the region close to the N-terminal ends of the helices of both the NTD and the ligand, the number of degrees of freedom remains very high and a structure of the full-length receptor will be required before we can fully

understand the details of this interface. Further complexities have been proposed by a mutational analysis of the NTD of the related glucagon receptor using cysteine accessibility approaches (Prévost *et al.*, 2010). A number of residues on one face of the NTD were found to be much less accessible to covalent modification than would have been expected from the GLP-1R NTD structures. However, these residues are on the opposite face of the NTD relative to the expected interface of the core domain and therefore may form an interface with another, as yet unidentified, protein.

Peptide–receptor interactions

Stage 1 interaction – binding of the ligand to the NTD

As described previously, the isolation of the NTD of GLP-1R as an independent soluble domain resulted in specific, though low affinity, binding of the natural ligand GLP-1. Since several mutations in the core domain of full-length GLP-1R resulted in a lowering of GLP-1 affinity, but not that of Ex4, it was hypothesized that Ex4 affinity was largely independent of the core domain (López de Maturana and Donnelly, 2002; Al-Sabah and Donnelly, 2003b). This was shown to be the case by demonstrating that the complete removal of the core domain has a minimal effect upon Ex4 affinity, compared with that of GLP-1, and that the interaction between Ex4 and the NTD was not dependent upon the N-terminal region of the ligand (López de Maturana *et al.*, 2003). A model was proposed to explain the distinct pharmacological properties of the two peptide agonists at the isolated NTD, with the suggestion that Ex4 formed an additional interaction (termed the 'Ex' interaction), which was due to one or more of the unique structural features of Ex4, such as its increased helicity, its C-terminal extension, or residues that were not conserved with GLP-1 (López de Maturana *et al.*, 2003). Runge *et al.* (2007) demonstrated that it was the increased helicity of Ex4, which accounted for its high affinity at the fully isolated NTD. However, when this domain was fused to the plasma membrane of HEK-293 cells via TM1, the large differential affinity observed at the isolated NTD of hGLP-1R was reduced to only eightfold (Mann *et al.*, 2010a,b) and, furthermore, in the presence of Brij micelles, the affinity of GLP-1 and Ex4 at the isolated NTD was similar (Schröder-Tittmann *et al.*, 2010).

The nine-residue C-terminal extension of Ex4 plays no significant role in the peptide's affinity at hGLP-1R (Runge *et al.*, 2007; Mann *et al.*, 2010a,b), which is in agreement with the X-ray structure of the isolated NTD bound with Ex4(9-39) (Runge *et al.*, 2008). However, Ser[32] in this extended region of the peptide is able to interact with Asp[68] in the NTD of rGLP-1R, generating a >20-fold improvement in affinity (Mann *et al.*, 2010a,b). The improved affinity of Ex4(9-39) at rGLP-1R, resulting from interaction between Ser[32] of the ligand and Asp[68] of the NTD, could be exchanged between hGLP-1 and rGLP-1R by swapping Glu and Asp at position 68. Hence, despite sharing similar physiochemical properties to Asp, Glu-68 does not appear to interact strongly with Ser[32] of the ligand. Given that Glu-68 interacts with the C-terminus of GLP-1 (Day *et al.*, 2010), it is possible that it preferentially interacts with residue 30 of Ex4(9-39), while the shorter Asp[68]

side chain in rGLP-1 interacts with Ser[32]. This would explain why the C-terminal extension on Ex4(9-39) improves the affinity for rGLP-1R but not hGLP-1R.

Photo-crosslinking of the C-terminal region of GLP-1 to GLP-1R demonstrated that residue 35 interacts with Glu-125, while residue 24 interacts with Glu-133 (Chen *et al.*, 2009). On the other hand, Ex4(9-39) retains high affinity for the isolated rGLP-1R NTD consisting of residues Gln-26–Glu-127, suggesting that the NTD from Glu-128 onwards is not required for binding the C-terminal half of the ligand (Mann *et al.*, 2007). The X-ray crystal structure of the hGLP-1R fragment Arg[24]–Tyr[145], with either Ex4(9-39) (Runge *et al.*, 2008) or GLP-1 (Underwood *et al.*, 2010), reveal the details of the interaction of the C-terminal region of the peptides and the NTD of the receptor. Figure 3A summarizes the structure of the NTD and how it binds to Ex4(9-39). The antagonist forms a well-defined helix from residues Leu[10]–Asn[28] and interacts with the NTD using residues within Glu[15]–Ser[32]. Although residues 9–14 do not interact with the NTD, residues 10–14 are nevertheless critical for high affinity binding (Runge *et al.*, 2007), presumably because they are required to stabilize the helical structure of the ligand. The α-helix of Ex4(9-39) is amphipathic (Figure 3B) and interacts with the NTD via residues on both faces, although it is the hydrophobic face which appears most important, with Val[19], Phe[22], Ile[23] and Leu[26] being buried in the binding site.

GLP-1 also forms an α-helix when bound to the NTD (Underwood *et al.*, 2010), but, in contrast to that in Ex4(9-39), it is kinked around Gly[22] as observed in earlier NMR studies (Thornton and Gorenstein, 1994). Residues Ala[24]–Val[33] interact with the NTD and, as with Ex4(9-39), the principal contacts are via a hydrophobic interface formed by residues Ala[24], Ala[25], Phe[28], Ile[29], Leu[32] and Val[33]. Because the hydrophobic faces of the helices of Ex4(9-39) and GLP-1 are highly conserved (López de Maturana and Donnelly, 2002), their interactions with the NTD are very similar.

However, differences at the hydrophilic faces result in a degree of differential affinity. The ability of Arg[20] of Ex4(9-39) to form intra-helical interactions with Glu[16] and Glu[17], and also for Lys[27] to interact intra-helically with Glu[24], results in stabilization of the α-helix (Figure 3B). However, three of these four charged sites are absent in GLP-1, and, moreover, Glu[16] is replaced by Gly[22], which reduces the helix stability and enables the distortion of this region. This hydrophilic surface may also be involved in a direct receptor interaction, since the crystal structures suggests that Arg[20] [Ex4(9-39)] and Lys[26] (GLP-1) may interact with Glu[128] of the NTD. However, truncation of the NTD to remove Glu[128] did not remove high Ex4(9-39) affinity (Mann *et al.*, 2007). On the other hand, Glu[127], which appears to interact with the antagonist but not GLP-1, could not be truncated without loss of Ex4(9-39) affinity, suggesting that the observed interaction with Lys[27] of the antagonist is important (Mann *et al.*, 2007). Mutagenesis of Glu[127] resulted in a sevenfold reduction of Ex4(9-39) affinity but with no effect upon GLP-1, suggesting it may be responsible for the differential affinity of these peptides at the NTD (Underwood *et al.*, 2010). Given that their differential affinity is about eightfold at the membrane-tethered NTD (Mann *et al.*, 2010b), the specific Glu[127] interaction may indeed account for this. In addition, the mutation of Leu[32], previously identified as a potential binding partner of Ex4(9-39)

(Mann *et al.*, 2007), also resulted in specific reduction of the antagonist's affinity, although the explanation for this is not obvious from the crystal structures (Underwood *et al.*, 2010). It may be that, since Leu[32] interacts with the ligand's helix close to the point at which GLP-1 kinks, it may have a differential interaction with the two ligands. Stabilization of the helix in this region of GLP-1, by substituting Ser[18] by Lys and Gly[22] by Glu, resulted in an eightfold increase in potency (Murage *et al.*, 2008; 2010).

Further studies have shown important ligand–receptor interactions points on the NTD. A polymorphism of GLP-1R, Thr[149]–Met (Beinborn *et al.*, 2005), resulted in a 60-fold reduction in affinity for GLP-1 but only fivefold reduction for Ex4, suggesting that this residue is involved in GLP-1 binding. However, the lack of a major effect on Ex4 affinity suggests that, either it does not interact with Thr[149], or else it interacts with a region not essential for affinity, such as the N-terminus. The latter seems likely since the close-by residue Tyr[145] has been labelled by a peptide probe containing benzoylphenylalanine (BPh) in place of Thr[12] of GLP-1 (Chen *et al.*, 2010b), and, furthermore, a similar ligand probe with BPh replacing Val[16] was found to cross-link to Leu[141] (Miller *et al.*, 2011). The importance of helix stability in this region has been discussed by Neumann *et al.* (2008), and, indeed, Thr[12] and Val[16] would be predicted to be separated by one helical turn. These data therefore complement the study of Murage *et al.* (2008), who demonstrated that stabilization of helical structure between Thr[11] and Gly[22], using lactam bridges, improved activity. Therefore, the region linking the NTD to TM1 appears to interact with the N-terminal region of GLP-1, although, as would be expected if this was the case, this region is not required for the high affinity of Ex4(9-39) since the NTD can be truncated between Glu[127] and Glu[128] (Mann *et al.*, 2007).

Stage 2 interaction – binding of the ligand to the core domain

Since there is no determined structure for the core domain of GLP-1R, our knowledge of the interaction between the peptide ligands and the core domain must be gleaned from more indirect approaches. The identification of mutations which reduce the affinity of GLP-1, but not that of GLP-1(15-36), have been useful for identifying residues in the core domain that interact with the N-terminus of GLP-1. For example, a double-alanine mutagenesis scan of ECL1 of rGLP-1R identified a residue pair Met[204]–Tyr[205] as interacting with GLP-1's N-terminal 8 residues (López de Maturana *et al.*, 2004). This approach has been validated by the identification of Tyr[205] as the attachment point of a photoactive analogue of GLP-1 containing a BPh at the N-terminus (Chen *et al.*, 2010b). While the scan of ECL1 suggested that it did not play a major role in ligand recognition (López de Maturana *et al.*, 2004), a number of charged and polar residues have been identified as being involved in ligand binding (Xiao *et al.*, 2000).

Further mutations with differential effects upon GLP-1 and GLP-1(15-36) affinity have been used to identify Asp[198] (TM2/ECL1; López de Maturana and Donnelly, 2002) and Lys[288] (TM4/ECL2; Al-Sabah and Donnelly, 2003b) as interaction points for the N-terminus of GLP-1. Furthermore, a double Ala-scan of ECL2 also identified a number of sites

Table 1

pIC$_{50}$ values for GLP-1 and GLP-1(15-36) at wild-type rGLP-1R expressed in HEK-293 cells and at site-directed mutations targeted at pairs of residues in ECL2 (Al-Sabah and Donnelly, unpublished)

	GLP-1(7-36) pIC$_{50}$	GLP-1(15-36) pIC$_{50}$
GLP-1R	8.5 ± 0.07	6.4 ± 0.02
W297A-T298A	6.5 ± 0.06	6.7 ± 0.27
R299A-N300A	6.1 ± 0.06	6.3 ± 0.06
Y305A-W306A	6.0 ± 0.13	6.2 ± 0.05
L307A-I308A	6.1 ± 0.09	6.0 ± 0.05
I309A-R310A	6.8 ± 0.08	6.5 ± 0.02

pIC$_{50}$ values were calculated from heterologous competition binding assays using ^{125}I-Ex4(9-39) tracer. Methodology, cell lines and reagents are as described in Al-Sabah and Donnelly (2003b). The mean ± SE is shown for three independent experiments each performed in triplicate and shows that the mutations remove the sensitivity of the receptor to the presence of the N-terminal region of GLP-1.

likely to be important in forming the binding site of the peptide's N-terminus (Table 1) and are also likely to be important for the agonist-induced activation of the receptor (Mann *et al.*, 2010a,b). However, ECL2 may also contact the mid-region of the peptide since BPh at position 20 of GLP-1 was photo-crosslinked to Trp[297] (Miller *et al.*, 2011). The use of GLP-1/glucagon chimaeric ligands, coupled with site-directed mutagenesis of the glucagon receptor, has shown that the reduced activity of an analogue of glucagon, with Ala at position 2, could be rescued by mutating Asp[385] to Glu, suggesting that the N-terminus binds close to the TM7/ECL3 boundary (Runge *et al.* 2003a,b).

A molecular modelling study, which incorporated the NTD X-ray studies (Runge *et al.*, 2008; Underwood *et al.*, 2010) with the outcome of several photo-crosslinking studies (Miller *et al.*, 2011; Chen *et al.*, 2009; Chen *et al.*, 2010b), predicted a deep binding pocket for His[7] of GLP-1, with Thr[11] close to the receptor sites Tyr[145] and Tyr[205]. Meanwhile Lys[26] and Leu[20] of GLP-1 were placed close to Glu[133] and Tyr[297] respectively (Miller *et al.*, 2011). However, without knowledge of the structures of the GLP-1R core domain structure and the receptor-bound ligand, it remains difficult to fully understand the details of the stage 2 interaction.

Non-peptide ligands

Non-peptidic agonists of GLP-1R would be desirable as therapeutic agents since they have the potential to be orally active and hence circumvent the current requirement for self-injection by patients. However, the first non-peptide ligand at GLP-1R was in fact an antagonist, T-0632, which competes with ^{125}I-Ex4(9-39) at hGLP-1R with an IC$_{50}$ of 1.2 μM and was able to antagonize GLP-1-induced cAMP production in COS-7 cells (Tibaduiza *et al.*, 2001). The compound was significantly less potent at rGLP-1R, and this species difference enabled the

identification of Trp[33] (Ser[33] in rGLP-1R) as being the critical residue. This residue is located on the α-helix of the NTD but is not involved in peptide binding – presumably the non-peptidic binding site over-laps with that of the peptide.

The first two non-peptide agonists of GLP-1R were published in 2007 (Chen *et al.*, 2007; Knudsen *et al.*, 2007). Boc5 and its analogue S4P were discovered through a screen of more than 48 000 synthetic and natural compounds that yielded two hits, which actually turned out to be due to the dimeric versions of the original compounds that had formed spontaneously during their long-term storage in DMSO. Boc5 acted as a full agonist with 1.08 μM potency at rGLP-1R expressed in HEK-293 cells using a Luciferase-based cAMP reporter assay. Ex4(9-39) blocked the Boc5-induced receptor response and also competed with ^{125}I-GLP-1 binding. Furthermore, Boc5 elicited a glucose-induced insulin response in isolated pancreatic islets from rat, inhibited food intake in rats and reduced HbA1c levels in *db/db* mice to non-diabetic levels. The GLP-1 mimetic properties of Boc5 were further characterized by Su *et al.* (2008).

The other class of non-peptidic agonist discovered in 2007 was 'Compound 2' (Cmp2; 6,7-dichloro-2methylsulfonyl-3-*N-tert*-butylaminoquinoxaline) and related structures (Knudsen *et al.*, 2007; Teng *et al.*, 2007). These compounds are significantly smaller than Boc5 and have distinct pharmacological properties. They are ago-allosteric modulators of hGLP-1R, since they can act both as independent agonists but also as allosteric enhancers of the activity of the natural agonist. In this case, the allosteric enhancement initially appeared to be limited to an increase in GLP-1 affinity (26-fold) rather than potency, probably due to a high degree of spare receptors. However, Cmp2 did potentiate the potency of GLP-1 in stable FlpIn-CHO cells expressing hGLP-1R (Koole *et al.*, 2010).

The concentration–response curves for Cmp2 are bell-shaped since higher concentrations are associated with cell death (Coopman *et al.*, 2010). Nevertheless, Cmp2 was able to stimulate glucose-dependent insulin secretion from normal mouse islets but not from those derived from GLP-1R knock-out mice (Knudsen *et al.*, 2007). Related quinoxaline compounds have also been synthesized and shown to display anti-diabetic activity (Bahekar *et al.*, 2007). A comparison of the effects of Cmp2 and GLP-1 in HEK-293 cells expressing hGLP-1R demonstrated that both agonists act via Gαs and that Cmp2 elicits 88% of the E_{max} of GLP-1 in cAMP assays (Coopman *et al.*, 2010). Interestingly, Cmp2's cAMP response was enhanced by Ex4(9-39), and, furthermore, the antagonist inhibited Cmp2-mediated receptor internalization. Further *in vivo* studies using mice demonstrated that, while Cmp2 failed to prominently enhance glucose-mediated insulin release when compared with the more potent peptidic drugs exenatide and liraglutide, it did nevertheless significantly decrease the overall glucose excursion (Irwin *et al.*, 2010). Ex4(9-39) did not impair Cmp2's glucoregulatory actions, consistent with this antagonist's inability to block Cmp2-induced cAMP activity *in vitro* (Knudsen *et al.*, 2007; Coopman *et al.*, 2010). Cmp2 also appears to possess peptide-dependent allosteric properties since it displayed clear enhancement of potency and affinity at GLP-1R for oxyntomodulin but not Ex4 (Koole *et al.*, 2010).

An interesting non-peptide response at GLP-1R has been shown using the flavanoid quercetin which, despite not being able to activate GLP-R directly, enhanced the potency of the Ca^{2+} response mediated by GLP-1 and Ex4 (Koole *et al.*, 2010). Using a range of flavanoid structures, the SAR between this pathway-selective behaviour and the flavanoid structure identified the 3-OH group as the key moiety of this activity (Wootten *et al.*, 2011).

The pharmacology of a novel pyrimidine-based compound has recently been published by Sloop *et al.* (2010). 'Compound B' (CmpB) was discovered from screening a pharmacophore-based focused compound library, followed by rational modifications of the initial hit. It is a full agonist at hGLP-1R but displayed poor potency (0.7 μM) that is more than 1000-fold lower than GLP-1 itself. Nevertheless, CmpB evoked insulin secretion in rats and was able to normalize insulin secretion in islets derived from a human donor with type 2 diabetes. CmpB was able to activate a truncated version of GLP-1R, which lacks the NTD, demonstrating that this non-peptide acts via the core domain. Ex4(9-39) did not antagonize the CmpB-response, further demonstrating that its mode of binding is distinct from that of the peptide ligands.

Conclusion

The case for targeting GLP-1R for the treatment of type 2 diabetes is clear, and therefore, knowledge of the details of the peptide ligands, the receptor itself and their mode of interaction is important. Much is now known about the structure and function of GLP-1R and of its natural ligand GLP-1, while some initial progress has been made in the discovery of non-peptidic agonists. Many of the key recognition elements of the peptide are known and the sites to which they bind on the receptor have been partly deduced. Nevertheless, a great deal of work has yet to be carried out before our understanding of this important hormone–receptor interaction is complete and before the use of non-peptidic therapeutics becomes a reality.

Acknowledgements

Conflict of interest

The author declares no conflict of interest.

References

Adelhorst K, Hedegaard BB, Knudsen LB, Kirk O (1994). Structure-activity studies of glucagon-like peptide-1. J Biol Chem 269: 6275–6278.

Ahrén B (2011). GLP-1 for type 2 diabetes. Exp Cell Res 317: 1239–1245.

Al-Sabah S, Donnelly D (2003a). A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors. Br J Pharmacol 140: 339–346.

Al-Sabah S, Donnelly D (2003b). The positive charge at Lys-288 of the glucagon-like peptide-1 (GLP-1) receptor is important for binding the N-terminus of peptide agonists. FEBS Lett 553: 342–346.

Al-Sabah S, Donnelly D (2004). The primary ligand-binding interaction at the GLP-1 receptor is via the putative helix of the peptide agonists. Protein Pept Lett 11: 9–14.

Andersen NH, Brodsky Y, Neidigh JW, Prickett KS (2002). Medium-dependence of the secondary structure of exendin-4 and glucagon-like-peptide-1. Bioorg Med Chem 10: 79–85.

Bahekar RH, Jain MR, Gupta AA, Goel A, Jadav PA, Patel DN et al. (2007). Synthesis and antidiabetic activity of 3,6,7-trisubstituted-2-(1H-imidazol-2-ylsulfanyl)quinoxalines and quinoxalin-2-yl isothioureas. Arch Pharm (Weinheim) 340: 359–366.

Baldwin JM (1993). The probable arrangement of the helices in G protein-coupled receptors. EMBO J 12: 1693–1703.

Bazarsuren A, Grauschopf U, Wozny M, Reusch D, Hoffmann E, Schaefer W et al. (2002). In vitro folding, functional characterization, and disulfide pattern of the extracellular domain of human GLP-1 receptor. Biophys Chem 96: 305–318.

Beinborn M, Worrall CI, McBride EW, Kopin AS (2005). A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness. Regul Pept 130: 1–6.

Bergwitz C, Gardella TJ, Flannery MR, Potts JT, Kronenberg HM, Goldring SR et al. (1996). Full activation of chimeric receptors by hybrids between parathyroid hormone and calcitonin. J Biol Chem 271: 26469–26472.

Burcelin R, Dolci W, Thorens B (1999). Long-lasting antidiabetic effect of a Dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1. Metabolism 48: 252–258.

Chen D, Liao J, Li N, Zhou C, Liu Q, Wang G et al. (2007). A non-peptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. Proc Natl Acad Sci U S A 104: 943–948.

Chen Q, Pinon DI, Miller LJ, Dong M (2009). Molecular basis for glucagon-like peptide 1 docking to its intact receptor studied with carboxyl-terminal photolabile probes. J Biol Chem 284: 34135–34144.

Chen Q, Miller LJ, Dong M (2010a). Role of N-linked glycosylation in biosynthesis, trafficking, and function of the human glucagon-like peptide 1 receptor. Am J Physiol Endocrinol Metab 299: E62–E68.

Chen Q, Pinon DI, Miller LJ, Dong M (2010b). Spatial approximations between residues 6 and 12 in the amino-terminal region of glucagon-like peptide 1 and its receptor. J Biol Chem 285: 24508–24518.

Coopman K, Huang Y, Johnston N, Bradley SJ, Wilkinson GF, Willars GB (2010). Comparative effects of the endogenous agonist glucagon-like peptide-1 (GLP-1)-(7-36) amide and the small-molecule ago-allosteric agent 'Compound 2' at the GLP-1 receptor. J Pharmacol Exp Ther 334: 795–808.

Cornu M, Thorens B (2009). GLP-1 protects beta-cells against apoptosis by enhancing the activity of an IGF-2/IGF1-receptor autocrine loop. Islets 1: 280–282.

D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW (1994). Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93: 2263–2266.

D'Alessio DA, Prigeon RL, Ensinck JW (1995). Enteral enhancement of glucose disposition by both insulin-dependant and insulin-independent processes. A physiological role of glucagon-like peptide I. Diabetes 44: 1433–1437.

Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J et al. (2009). A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 5: 749–757.

Day JW, Li P, Patterson JT, Chabenne J, DiMarchi Chabenne M, Gelfanov VM et al. (2010). Charge inversion at position 68 of the glucagon and glucagon-like peptide-1 receptors supports selectivity in hormone action. J Pept Sci 17: 218–225.

Deacon CF, Johnsen AH, Holst JJ (1995). Degradation of glucagon-like peptide01 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80: 952–957.

Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ (1998). Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 41: 271–278.

Devigny C, Perez-Balderas F, Hoogeland B, Cuboni S, Wachtel R, Mauch CP et al. (2011). Biomimetic screening of class-B G protein-coupled receptors. J Am Chem Soc 133: 8927–8933.

Dillon JS, Tanizawa Y, Wheeler MB, Leng X-H, Ligon BB, Rabin DU et al. (1993). Cloning and functional expression of the human glucagon-like peptide-1 (GLP-1) receptor. Endocrinology 133: 1907–1910.

Dong M, Pinon DI, Asmann YW, Miller LJ (2006). Possible endogenous agonist mechanism for the activation of secretin family G protein-coupled receptors. Mol Pharm 70: 206–213.

Dong M, Gao F, Pinon DI, Miller LJ (2008). Insights into the structural basis of endogenous agonist activation of family B G protein-coupled receptors. Mol Endocrinol 22: 1489–1499.

Donnelly D (1997). The arrangement of the transmembrane helices in the secretin receptor family of G-protein-coupled receptors. FEBS Lett 409: 431–436.

Donnelly D, Johnson MS, Blundell TL, Saunders J (1989). An analysis of the periodicity of conserved residues in sequence alignments of G-protein coupled receptors. FEBS Lett 251: 109–116.

Donnelly D, Findlay JBC, Blundell TL (1994). The evolution and structure of aminergic G protein-coupled receptors. Receptors Channels 2: 61–78.

Doyle ME, Egan JM (2007). Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 113: 546–593.

Doyle ME, Theodorakis MJ, Holloway HW, Bernier M, Greig NH, Egan JM (2003). The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity. Regul Pept 114: 153–158.

Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF (1987). Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 84: 3434–3438.

Edwards CMB, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA *et al*. (1999). Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans. Diabetes 48: 86–93.

Egan JM, Meneilly GS, Habener JF, Elahi D (2002). Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab 87: 3768–3773.

Elahi D, Egan JM, Shannon RP, Meneilly GS, Khatri A, Habener JF *et al*. (2008). GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide. Obesity 16: 1501–1509.

Eng J, Andrews PC, Kleinman WA, Singh L, Raufman J-P (1990). Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom. J Biol Chem 265: 20259–20262.

Eng J, Kleinman WA, Singh L, Singh G, Raufman J-P (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. J Biol Chem 267: 7402–7405.

Flint A, Raben A, Astrup A, Holst JJ (1998). Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101: 515–520.

Frimurer TM, Bywater RP (1999). Structure of the intergral membrane domain of the GLP1 receptor. Proteins 35: 375–386.

Gallwitz B, Schmidt WE, Conlon JM, Creutzfeldt W (1990). Glucagon-like peptide-1 (7-36) amide: characterization of the domain responsible for binding to its receptor on rat insulinoma RINm5F cells. J Mol Endocrinol 5: 33–39.

Gallwitz B, Witt M, Paetzold G, Morays-Wortmann C, Zimmermann B, Eckart K *et al*. (1994). Structure/activity characterization of glucagon-like peptide-1. Eur J Biochem 225: 1151–1156.

Göke R, Fehmann H-C, Linn T, Schmidt H, Krause M, Eng J *et al*. (1993). Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. J Biol Chem 268: 19650–19655.

Göke R, Just R, Lankat-Buttgereit B, Göke B (1994). Glycosylation of the GLP-1 receptor is a prerequisite for regular receptor function. Peptides 15: 675–681.

Gong N, Ma A-N, Zhang L-J, Luo X-S, Zhang Y-H, Xu M *et al*. (2011). Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity. Br J Pharmacol 163: 399–412.

Graziano MP, Hey PJ, Borkowski D, Chicchi GG, Strader CD (1993). Cloning and functional expression of a human glucagon-like peptide-1 receptor. Biochem Biophys Res Commun 196: 141–146.

Hällbrink M, Holmqvist T, Olsson M, Östenson C-G, Efendic S, Langel Ü (2001). Different domains in the third intracellular loop of the GLP-1 receptor are responsible for Gαs and Gαi/Gαo activation. Biochim Biophys Acta 1546: 79–86.

Hansen L, Deacon CF, Ørskov C, Holst JJ (1999). Glucagon-LikePeptide-1-(7-36) amide is transformed to glucagon-like peptide-1-(9-36) amide by Dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140: 5356–5363.

Hareter A, Hoffman E, Bode H-P, Göke B, Göke R (1997). The positive charge of the imidazole side chain of Histidine7 is crucial for GLP-1 action. Endocr J 44: 701–705.

Harikumar KG, Pinon DI, Miller LJ (2007). Transmembrane segment IV contributes a functionally important interface for oligomerization of the class II G protein-coupled secretin receptor. J Biol Chem 282: 30363–30372.

Harikumar KG, Ball AM, Sexton PM, Miller LJ (2010). Importance of lipid-exposed residues in transmembrane segment four for family B calcitonin receptor homo-dimerization. Regul Pept 164: 113–119.

Heller RS, Kieffer TJ, Habener JF (1996). Point mutations in the first and third intracellular loops of the glucagon-like peptide-1 receptor alter intracellular signaling. Biochem Biophys Res Commun 223: 624–632.

Hjorth SA, Schwartz TW (1996). Glucagon and GLP-1 receptors: lessons from chimeric ligands and receptors. Acta Physiol Scand 157: 343–345.

Hjorth SA, Adelhorst K, Brogaard Pedersen B, Kirk O, Schwartz TW (1994). Glucagon and glucagon-like peptide 1: selective receptor recognition via distinct peptide epitopes. J Biol Chem 269: 30121–30124.

Hoare SRJ (2005). Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. Drug Discov Today 10: 417–427.

Holst JJ, Ørskov C, Vagn Nielsen O, Schwartz TW (1987). Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 211: 169–174.

Huang Y, Wilkinson GF, Willars GB (2010). Role of the signal peptide in the synthesis and processing of the glucagon-like peptide-1 receptor. Br J Pharmacol 159: 237–251.

Iltz JL, Baker DE, Setter SM, Campbell RK (2006). Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. Clin Ther 28: 652–665.

Irwin DM, Satkunarajah M, Wen Y, Brubaker PL, Pederson RA, Wheeler MB (1997). The Xenopus proglucagon gene encodes novel GLP-1-like peptides with insulinotropic properties. Proc Natl Acad Sci U S A 94: 7915–7920.

Irwin N, Flatt PR, Patterson S, Green BD (2010). Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6, 7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline. Eur J Pharmacol 628: 268–273.

Knudsen LB, Pridal L (1996). Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 318: 429–435.

Knudsen LB, Kiel D, Teng M, Behrens C, Bhumralkar D, Kodra JT *et al*. (2007). Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc Natl Acad Sci U S A 104: 937–942.

Kolligs F, Fehmann H-C, Göke R, Göke B (1995). Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-36) amide. Diabetes 44: 16–19.

Koole C, Wootten D, Simms J, Valant C, Sridhar R, Woodman OL *et al*. (2010). Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol Pharmacol 78: 456–465.

Kreymann B, Williams G, Ghatei MA, Bloom SR (1987). Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 330: 1300–1304.

Lin F, Wang R (2009). Molecular modelling of the three-dimensional structure of GLP-IR and its interactions with several agonists. J Mol Model 15: 53–65.

López de Maturana R, Donnelly D (2002). The glucagon-like peptide-1 receptor binding site for the N-terminus of GLP-1 requires polarity at Asp198 rather than negative charge. FEBS Lett 530: 244–248.

López de Maturana R, Willshaw A, Kuntzsch A, Rudolph R, Donnelly D (2003). The isolated N-terminal domain of the Glucagon-like Peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1. J Biol Chem 278: 10195–10200.

López de Maturana R, Treece-Birch J, Abidi F, Findlay JB, Donnelly D (2004). Met-204 and Tyr-205 are together important for binding GLP-1 receptor agonists but not their N-terminally truncated analogues. Protein Pept Lett 11: 15–22.

Mann R, Nasr N, Hadden D, Sinfield J, Abidi F, Al-Sabah S et al. (2007). Peptide binding at the GLP-1 receptor. Biochem Soc Trans 35: 713–716.

Mann RJ, Al-Sabah S, López de Maturana R, Sinfield JK, Donnelly D (2010a). Functional coupling of Cys-226 and Cys-296 in the glucagon-like peptide-1 (GLP-1) receptor indicates a disulfide bond that is close to the activation pocket. Peptides 31: 2289–2293.

Mann RJ, Nasr NE, Sinfield JK, Paci E, Donnelly D (2010b). The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4. Br J Pharmacol 160: 1973–1984.

Mapelli C, Natarajan SI, Meyer JP, Bastos MM, Bernatowicz MS, Lee VG et al. (2009). Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity. J Med Chem 52: 7788–7799.

Mathi SK, Chan Y, Li X, Wheeler MB (1997). Scanning of the Glucagon-Like Peptide-1 Receptor localizes G protein-activating determinants primarily to the N terminus of the third intracellular loop. Mol Endocrinol 11: 424–432.

McIntyre N, Holdsworth CD, Turner DS (1964). New interpretation of oral glucose tolerance. Lancet 284: 20–21.

Miller LJ, Chen Q, Lam PC-H, Pinon DI, Sexton PM, Abagyan R et al. (2011). Refinement of glucagon-like peptide 1 docking to its intact receptor using mid-region photolabile probes and molecular modeling. J Biol Chem 286: 15895–15907.

Mojsov S (1992). Structural requirements for biological activity of glucagon-like peptide-I. Int J Peptide Protein Res 40: 333–343.

Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF (1986). Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 261: 11880–11889.

Mojsov S, Weir GC, Habener JF (1987). Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79: 616–619.

Montrose-Rafizadeh C, Yang H, Rodgers BD, Beday A, Pritchette LA, Eng J (1997). High potency antagonists of the pancreatic glucagon-like peptide-1 receptor. J Biol Chem 272: 21201–21206.

Murage EN, Schroeder JC, Beinborn M, Ahn J-M (2008). Search for alpha-helical propensity in the receptor-bound conformation of glucagon-like peptide-1. Bioorg Med Chem 16: 10106–10112.

Murage EN, Gao G, Bisello A, Ahn J-M (2010). Development of potent glucagon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges. J Med Chem 53: 6412–6420.

Nathan DM, Schreiber E, Fogel H, Majsov S, Habener JF (1992). Insuilinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15: 270–276.

Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Erbert R et al. (1986). Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63: 492–498.

Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Erbert R, Creutzfeldt W (1993). Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91: 301–307.

Nauck MA, Wollschläger D, Werner J, Holst JJ, Ørskov C, Creutzfeldt W et al. (1996). Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 39: 1546–1553.

Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Ørskov C, Ritzel R et al. (1997). Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273: E981–E988.

Neidigh JW, Andersen NH (2002). Peptide conformational changes induced by tryptophan-phosphocholine interactions in a micelle. Biopolymers 65: 354–361.

Neidigh JW, Fesinmeyer RW, Prickett KS, Andersen NH (2001). Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in the solution and micelle-associated states. Biochemistry 40: 13188–13200.

Neidigh JW, Fesinmeyer RM, Andersen NH (2002). Designing a 20-residue protein. Nat Struct Biol 9: 425–430.

Neumann J-M, Couvineau A, Murail S, Lacapère J-J, Jamin N, Laburthe M (2008). Class-B GPCR activation: is ligand helix-capping the key? Trends Biochem Sci 33: 314–319.

Neumiller JJ, Campbell RK (2009). Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Ann Pharmacother 43: 1433–1444.

Ørskov C, Nielsen JH (1988). Truncated glucagon-like peptide-1 (proglucagon 78-107 amide), an intestinal insulin-releasing peptide, has specific receptors on rat insulinoma cells (RIN 5AH). FEBS Lett 229: 175–178.

Ørskov C, Wettergren A, Holst JJ (1993). Biological effects and metabolic rates of glucagon-like peptide-1 7-36 amide and glucagon-like peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 42: 658–661.

Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fo BA et al. (2000). Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289: 739–745.

Parker JC, Andrews KM, Rescek DM, Massefski W, Andrews GC, Contillo LG et al. (1998). Structure-function analysis of a series of glucagon-like peptide-1 analogs. J Pept Res 52: 398–409.

Parthier C, Reedtz-Runge S, Rudoloh R, Stubbs MT (2009). Passing the baton in class B GPCRs: peptide hormone activation via helix induction? Trends Biochem Sci 34: 303–310.

Patterson JT, Day JW, Gelfanov VM, DiMarchi RD (2011a). Functional association of the N-terminal residues with the central region in glucagon-related peptides. J Pept Sci 17: 659–666.

Patterson JT, Ottaway N, Gelfanov VM, Smiley DL, Perez-Tilve D, Pfluger PT et al. (2011b). A novel human-based receptor antagonist of sustained action reveals body weight control by endogenous GLP-1. ACS Chem Biol 6: 135–145.

Perfetti R, Hui H (2004). The role of GLP-1 in the life and death of pancreatic beta cells. Horm Metab Res 36: 804–810.

Prévost M, Vertongen P, Raussens V, Roberts DJ, Cnuddle J, Perret J et al. (2010). Mutational and cysteine scanning analysis of the glucagon receptor N-terminal domain. J Biol Chem 285: 30951–30598.

Raufman J-P, Singh L, Eng J (1991). Exendin-3, a novel peptide from Heloderma horridum venom, interacts with vasoactive intestinal peptide receptors and a newly described receptor on dispersed acini from guinea pig pancreas. J Biol Chem 266: 2897–2902.

Raufman J-P, Singh L, Singh G, Eng J (1992). Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. J Biol Chem 267: 21432–21437.

Runge A, Schimmer S, Oschmann J, Schiødt CB, Knudsen SM, Jeppesen CB et al. (2007). Differential structural properties of GLP-1 and exendin-4 determine their relative affinity for the GLP-1 receptor N-terminal extracellular domain. Biochemistry 46: 5830–5840.

Runge S, Gram C, Bräuner-Osborne H, Madsen K, Knudsen LB, Wulff BS (2003a). Three distinct epitopes on the extracellular face of the glucagon receptor determine specificity for the glucagon amino terminus. J Biol Chem 278: 28005–28010.

Runge S, Wulff BS, Madsen K, Bräuner-Osborne H, Knudsen LB (2003b). Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity. Br J Pharmacol 138: 787–794.

Runge S, Thøgersen H, Madsen K, Lau J, Rudolph R (2008). Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. J Biol Chem 283: 11340–11347.

Salapatek A-MF, MacDonald PE, Gaisano HY, Wheeler MB (1999). Mutations to the Third Cytoplasmic Domain of the Glucagon-Like Peptide 1 (GLP-1) Receptor Can Functionally Uncouple GLP-1-Stimulated Insulin Secretion in HIT-T15 Cells. Mol Endocrinol 13: 1305–1317.

Schepp W, Schmidtler J, Riedel T, Dehne K, Schusdziarra V, Holst JJ et al. (1994). Exendin-4 and exendin-(9-39)-amide: agonist and antagonist, respectively at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)-amide. Eur J Pharmacol 269: 183–191.

Schröder-Tittmann K, Bosse-Doenecke E, Reedtz-Runge S, Ihling C, Sinz A, Tittmann K et al. (2010). Recombinant expression, in vitro refolding, and biophysical characterization of the human glucagon-like peptide-1 receptor. Biochemistry 49: 7956–7965.

Segre GV, Goldring SR (1993). Receptors for secretin, calcitonin, parathyroid hormone (PTH)/PTH-related peptide, vasoactive intestinal peptide, glucagonlike peptide 1, growth hormone-releasing hormone, and glucagon belong to a newly discovered G-protein-linked receptor family. Trends Endocrinol Metab 4: 309–314.

Serre V, Dolci W, Schaerer E, Scrocchi L, Drucker D, Efrat S et al. (1998). Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3′, 5′- monophosphate levels and β-cell glucose competence. Endocrinology 139: 4448–4454.

Siegel EG, Gallwitz B, Scharf G, Mentlein R, Morys-Wortmann C, Fölsch UR et al. (1999). Biological activity of GLP-1-analogues with N-terminal modifications. Regul Pept 79: 93–102.

Sloop KW, Willard FS, Brenner MB, Ficorilli J, Valasek K, Showalter AD et al. (2010). Novel small molecule glucagon-like peptide-1 agonist stimulates insulin secretion in rodents and from human islets. Diabetes 59: 3099–3107.

Su H, He M, Li H, Liu Q, Wang J, Wang Y et al. (2008). Boc5, a non-peptidic glucagon-like peptide-1 receptor agonist, invokes sustained glycemic control and weight loss in diabetic mice. PLoS ONE 3: 1–11.

Suzuki S, Kawai K, Ohashi S, Mukai H, Yamashita K (1989). Comparison of the effects of various C-terminal and N-terminal fragment peptides of glucagon-like peptide-1 on insulin and glucagon release from the isolated perfused rat pancreas. Endocrinology 125: 3109–3114.

Syme CA, Zhang L, Bisello A (2006). Caveolin-1 regulates cellular trafficking and function in the glucagon-like peptide 1 receptor. Mol Endocrinol 20: 3400–3411.

Takhar A, Gyomorey S, Su R-C, Mathi SK, Li X, Wheeler MB (1995). The third cytoplasmic domain of the GLP-1[7-36 amide] receptor is required for coupling to the adenylyl cyclase system. Endocrinology 137: 2175–2178.

Tams JW, Knudsen SM, Fahrenkrug J (1998). Proposed arrangement of the seven transmembrane helices in the secretin receptor family. Receptors Channels 5: 79–90.

Teng M, Johnson MD, Thomas C, Kiel D, Lakis JN, Kercher T et al. (2007). Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor. Bioorg Med Chem Lett 17: 5472–5478.

Thorens B (1992). Expression cloning of the pancreatic β cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci U S A 89: 8641–8645.

Thorens B, Porett A, Bühler L, Deng SP, Morel P, Widmann C (1993). Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42: 1678–1682.

Thornton K, Gorenstein DG (1994). Structure of glucagon-like peptide (7-36) amide in a dodecylphosphocholine micelle as determined by 2D NMR. Biochemistry 33: 3532–3539.

Tibaduiza EC, Chen C, Beinborn M (2001). A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain. J Biol Chem 276: 37787–37793.

Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CMB, Meeran K et al. (1996). A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379: 69–72.

Underwood CR, Garibay P, Knudsen LB, Hastrup S, Peters GH, Rudolph R et al. (2010). Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor. J Biol Chem 285: 723–730.

Vahl TP, Paty BW, Fuller BD, Prigeon RL, D'Alessio DA (2003). Effects of GLP-1-(7-36) amide, GLP-1-(7-37), and GLP-1-(9-36) amide on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 88: 1772–1779.

Wang S, Yu J, Li W, Li F (2010). Structural study of an active analog of EX-4 in solution and micelle associated states. Biopolymers (Peptide Science) 96: 348–357.

Watanabe Y, Kawai K, Oshashi S, Yokota C, Suzuki S, Yamashita K (1994). Structure-activity relationships of glucagon-like peptide-1 (7-36) amide: insulinotropic activities in perfused rat pancreases, and receptor binding and cyclic AMP production in RINm5F cells. J Endocrinol 140: 45–52.

Weir GC, Mojsov S, Hendrick GK, Habener JF (1989). Glucagon-like peptide I (7-37) actions on endocrine pancreas. Diabetes 38: 338–342.

Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ (1993). Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38: 665–673.

Widmann C, Dolci W, Thorens B (1995). Agonist-induced internalization and recycling of the glucagon-like peptide-1 receptor in transfected fibroblasts and in insulinomas. Biochem J 310: 203–214.

Widmann C, Dolci W, Thorens B (1996a). Desensitization and phosphorylation of the glucagon-like peptide-1 (GLP-1) receptor by GLP-1 and 4-Phorbol 12-Myristate 13-Acetate. Mol Endocrinol 10: 62–75.

Widmann C, Dolci W, Thorens B (1996b). Heterologous desensitization of the glucagon-like peptide-1 receptor by phorbol

esters requires phosphorylation of the cytoplasmic tail at four different sites. J Biol Chem 271: 19957–19963.

Wilmen A, Göke B, Göke R (1996). The isolated N-terminal extracellular domain of the glucagon-like peptide-1 (GLP)-1 receptor has intrinsic binding activity. FEBS Lett 398: 43–47.

Wootten D, Simms J, Koole C, Woodman OL, Summers RJ, Christopoulos A *et al*. (2011). Modulation of the glucagon-like peptide-1 receptor signaling by naturally occurring and synthetic flavonoids. J Pharmacol Exp Ther 336: 540–550.

Xiao Q, Jeng W, Wheeler MB (2000). Characterization of glucagon-like peptide-1 receptor binding determinants. J Mol Endocrinol 25: 321–335.

Xiao Q, Giguere J, Parisen M, Jeng WS, Pierre PL, Brubaker PL *et al*. (2001). Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. Biochemistry 40: 2860–2869.